Current and historical daily PE Ratio for Kiniksa Pharmaceuticals Ltd (
) from 2018 to May 29 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Kiniksa Pharmaceuticals stock (KNSA) PE ratio as of May 29 2024 is 169.73.
More Details
Kiniksa Pharmaceuticals Ltd (KNSA) PE Ratio (TTM) Chart
Kiniksa Pharmaceuticals Ltd (KNSA) PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Total 1239
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Kiniksa Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-30 | 169.4 | 2024-03-26 | 110.9 |
| 2024-05-29 | 169.4 | 2024-03-25 | 110.9 |
| 2024-05-28 | 173.1 | 2024-03-22 | 110.9 |
| 2024-05-24 | 173.2 | 2024-03-21 | 110.0 |
| 2024-05-23 | 174.3 | 2024-03-20 | 109.9 |
| 2024-05-22 | 175.2 | 2024-03-19 | 109.4 |
| 2024-05-21 | 176.1 | 2024-03-18 | 108.8 |
| 2024-05-20 | 178.8 | 2024-03-15 | 111.1 |
| 2024-05-17 | 179.7 | 2024-03-14 | 113.1 |
| 2024-05-16 | 182.8 | 2024-03-13 | 113.7 |
| 2024-05-15 | 182.7 | 2024-03-12 | 113.6 |
| 2024-05-14 | 177.1 | 2024-03-11 | 113.0 |
| 2024-05-13 | 178.0 | 2024-03-08 | 115.6 |
| 2024-05-10 | 177.6 | 2024-03-07 | 118.1 |
| 2024-05-09 | 183.6 | 2024-03-06 | 116.7 |
| 2024-05-08 | 184.2 | 2024-03-05 | 112.1 |
| 2024-05-07 | 184.8 | 2024-03-04 | 112.2 |
| 2024-05-06 | 181.7 | 2024-03-01 | 120.8 |
| 2024-05-03 | 182.6 | 2024-02-29 | 117.4 |
| 2024-05-02 | 176.2 | 2024-02-28 | 113.1 |
| 2024-05-01 | 176.4 | 2024-02-27 | 116.1 |
| 2024-04-30 | 170.2 | 2024-02-26 | 112.0 |
| 2024-04-29 | 168.6 | 2024-02-23 | 111.1 |
| 2024-04-26 | 162.6 | 2024-02-22 | 109.6 |
| 2024-04-25 | 160.1 | 2024-02-21 | 110.9 |
| 2024-04-24 | 162.4 | 2024-02-20 | 110.7 |
| 2024-04-23 | 160.7 | 2024-02-16 | 110.8 |
| 2024-04-22 | 155.4 | 2024-02-15 | 112.1 |
| 2024-04-19 | 153.7 | 2024-02-14 | 110.5 |
| 2024-04-18 | 153.4 | 2024-02-13 | 110.3 |
| 2024-04-17 | 154.1 | 2024-02-12 | 114.2 |
| 2024-04-16 | 158.7 | 2024-02-09 | 112.7 |
| 2024-04-15 | 158.6 | 2024-02-08 | 105.7 |
| 2024-04-12 | 157.2 | 2024-02-07 | 100.7 |
| 2024-04-11 | 160.9 | 2024-02-06 | 102.7 |
| 2024-04-10 | 158.6 | 2024-02-05 | 102.7 |
| 2024-04-09 | 161.2 | 2024-02-02 | 102.1 |
| 2024-04-08 | 160.7 | 2024-02-01 | 101.2 |
| 2024-04-05 | 162.7 | 2024-01-31 | 97.9 |
| 2024-04-04 | 164.2 | 2024-01-30 | 99.7 |
| 2024-04-03 | 165.8 | 2024-01-29 | 102.2 |
| 2024-04-02 | 170.3 | 2024-01-26 | 101.2 |
| 2024-04-01 | 179.1 | 2024-01-25 | 101.9 |
| 2024-03-28 | 179.4 | 2024-01-24 | 101.9 |
| 2024-03-27 | 111.1 | 2024-01-23 | 103.8 |
Kiniksa Pharmaceuticals Ltd (KNSA) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Kiniksa Pharmaceuticals Ltd
NAICS : 325412
SIC : 2836
ISIN : BMG5269C1010
Share Class Description:
KNSA: Class ADescription
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers